Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Oehler

Showing results (81-90 of 107) with videos related to

Pageof 11
Sort By:
Haematologica|May 5, 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemiaKathryn E Flynn, Ehab Atallah, Li Lin, et al.
Plos One|August 23, 2013
The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemiaEra L Pogosova-Agadjanyan, Kenneth J Kopecky, Fabiana Ostronoff, et al.
Cancer Immunology Research|June 26, 2025
SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid NeoplasmsMelinda A Biernacki, Jessica Lok, Kimberly A Foster, et al.
Oncogene|November 18, 2020
AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growthIta Novita Sari, Ying-Gui Yang, Yoseph Toni Wijaya, et al.
JAMA Network Open|December 18, 2023
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid LeukemiaAaron N Winn, Ehab Atallah, Jorge Cortes, et al.
Cancer|December 21, 2021
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemiaKelsey-Leigh A Garcia, Sindhu Cherian, Philip A Stevenson, et al.
Cancers|June 24, 2022
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsColin D Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Leukemia|January 13, 2019
The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemiaVan T Hoang, Divij Verma, Parimala Sonika Godavarthy, et al.
American Journal of Hematology|August 4, 2018
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study resultsJorge E Cortes, B Douglas Smith, Eunice S Wang, et al.
Haematologica|April 26, 2019
The vascular bone marrow niche influences outcome in chronic myeloid leukemia <i>via</i> the E-selectin - SCL/TAL1 - CD44 axisParimala Sonika Godavarthy, Rahul Kumar, Stefanie C Herkt, et al.
Pageof 11

Showing results (81-90 of 107) with videos related to

Sort By:
Pageof 11
Haematologica|May 5, 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemiaKathryn E Flynn, Ehab Atallah, Li Lin, et al.
Plos One|August 23, 2013
The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemiaEra L Pogosova-Agadjanyan, Kenneth J Kopecky, Fabiana Ostronoff, et al.
Cancer Immunology Research|June 26, 2025
SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid NeoplasmsMelinda A Biernacki, Jessica Lok, Kimberly A Foster, et al.
Oncogene|November 18, 2020
AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growthIta Novita Sari, Ying-Gui Yang, Yoseph Toni Wijaya, et al.
JAMA Network Open|December 18, 2023
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid LeukemiaAaron N Winn, Ehab Atallah, Jorge Cortes, et al.
Cancer|December 21, 2021
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemiaKelsey-Leigh A Garcia, Sindhu Cherian, Philip A Stevenson, et al.
Cancers|June 24, 2022
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsColin D Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Leukemia|January 13, 2019
The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemiaVan T Hoang, Divij Verma, Parimala Sonika Godavarthy, et al.
American Journal of Hematology|August 4, 2018
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study resultsJorge E Cortes, B Douglas Smith, Eunice S Wang, et al.
Haematologica|April 26, 2019
The vascular bone marrow niche influences outcome in chronic myeloid leukemia <i>via</i> the E-selectin - SCL/TAL1 - CD44 axisParimala Sonika Godavarthy, Rahul Kumar, Stefanie C Herkt, et al.
Pageof 11